Clinical trial Recruiting at 1 site Observational Ages 16 and up

Linking autonomic nervous system function to acute graft-versus-host disease

Official title: A Cohort Study on the Association Between the Autonomic Nervous System Function and Acute GvHD After Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation

Run by Institute of Hematology & Blood Diseases Hospital, China · NCT07374874 · Data updated 2026-11-12

This study tests whether monitoring autonomic nervous system (ANS) function can help detect acute graft-versus-host disease early in patients receiving HLA-haploidentical transplants.

Quick facts

Study typeObservational
Ages16 Years and up
SexAll
Enrollment60 (estimated)
SponsorInstitute of Hematology & Blood Diseases Hospital, China
Academic / other
Locations1 site (Tianjin, Tianjin Municipality)
StatusRecruiting
StartedDecember 18, 2025
Main results expectedDecember 15, 2026
Study endsJanuary 1, 2027
Registry record updatedJanuary 29, 2026
Trial IDNCT07374874 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are patients older than 16 receiving HLA-haploidentical hematopoietic transplants who can give informed consent and comply with monitoring procedures.

Probably not a fit

Patients undergoing tandem or multiple transplants, those with mental or medical conditions preventing compliance, or those judged to be at high risk from participation are unlikely to benefit from this protocol.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective observational cohort of HLA-haploidentical hematopoietic transplant recipients aged over 16. Researchers will monitor autonomic nervous system (ANS) function around the transplant period using physiological measurements and apply a predictive model to classify risk of acute graft-versus-host disease (aGvHD). No interventional treatments are assigned; clinical care follows standard practice while data are collected. The aim is to determine whether changes in ANS signals precede or correlate with aGvHD onset and could support earlier detection.

Why it matters

Potential benefit: If successful, this approach could allow earlier detection of aGvHD through ANS monitoring, enabling quicker treatment and potentially reducing complications.

How similar studies have gone: Some preliminary work has linked ANS measures (for example heart rate variability) to immune and transplant outcomes, but using ANS function specifically to predict aGvHD remains exploratory.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Patients must be \> 16 years of age;
2. Patients receiving HLA-haploidentical transplants;
3. Patients have to sign an informed consent form before the start of the research procedure.

Exclusion Criteria:

1. Tandem transplantation or multiple transplantations;
2. Mental or other medical conditions that make the patients unable to comply with the research treatment and monitoring requirements;
3. Patients who are ineligible for the study due to other factors, or will bear great risk if participating in the study.

Where it's running

  • Institute of Hematology & Blood Diseases Hospital
    Tianjin, Tianjin Municipality, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.